Meanwhile, Allergan acquires drug developer Naurex in a $560 million deal. 

The deal would create one of the five biggest generic drugmakers in the U.S.

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

As the United States edges ever closer to the dreaded fiscal cliff, the pharmaceutical industry approaches a precipice of its own.